A comparison of key features of patients with 17p deletion treated with CFAR versus historic high-risk group treated with FCR
| Parameter . | CFAR (n = 14) . | FCR (n = 18) . |
|---|---|---|
| CR | 57%* | 17%* |
| ORR | 79% | 67% |
| Median PFS | 15 mo | 12 mo |
| Median OS | 25+ mo | 55 mo |
| Parameter . | CFAR (n = 14) . | FCR (n = 18) . |
|---|---|---|
| CR | 57%* | 17%* |
| ORR | 79% | 67% |
| Median PFS | 15 mo | 12 mo |
| Median OS | 25+ mo | 55 mo |
FCR indicates fludarabine, cyclophosphamide, and rituximab; CFAR, alemtuzumab added to FCR; CR, complete remission; ORR, overall response rate; PFS, progression-free survival; and OS, overall survival.
Fisher exact, 2-tailed test P = .03.